The considerations that manufacturers use in setting prices for curative treatments like gene therapy for sickle cell disease must go beyond a calculation of medical costs avoided and take into account factors such as existing co-morbidities, Sen. Bill Cassidy, R-La., advised at a policy conference in Washington DC Feb. 12.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?